Improvement of overall survival in patients with cutaneous melanoma at a tertiary care center in Germany from 2001 to 2020

Q: What does this research mean for the field?

Overall survival for patients with stage II-IV cutaneous melanoma has significantly improved in real-world settings since 2011, reflecting the impact of new systemic treatments, although relapse-free survival has remained unchanged. Novelty: ClaimNovelty.CONFIRMATORY. Consensus alignment: ConsensusAlignment.NEUTRAL.

Lena Nanz; Claus Garbe; Markus Reitmajer; Andrea Forschner; Yves Maczey‐Leber; Teresa Amaral; Lukas Flatz; Ulrike Leiter

doi:10.1111/ddg.70470

September 7, 2026JDDG Journal der Deutschen Dermatologischen GesellschaftOpen Access

Improvement of overall survival in patients with cutaneous melanoma at a tertiary care center in Germany from 2001 to 2020

View Full Paper

Ask AI

Bookmark

Share

Key Points

Determine whether real-world overall survival and relapse-free survival in cutaneous melanoma improved following the introduction of novel systemic treatments after 2011.
Analyzed N=10,270 patients with cutaneous melanoma at a single tertiary care center in Germany.
Conducted Kaplan-Meier survival analyses comparing patients diagnosed between 2001–2010 (n=4,846) with those diagnosed between 2011–2020 (n=5,424) for overall survival and relapse-free survival across disease stages.
Five-year overall survival improved between 2001–2010 and 2011–2020 cohorts in stage II (78.2% vs 85.2%), stage III (56.5% vs 70.7%), and stage IV (9.8% vs 34.6%), but remained unchanged in stage I (95.9% vs 96.2%).
Five-year relapse-free survival showed no differences between the 2001–2010 and 2011–2020 cohorts in stage I (93.6% vs 93.1%), stage II (66.9% vs 64.3%), or stage III (38.2% vs 42.5%).

No abstract yet

We only have this paper's title and publication details.

Read it at the source

Implication

Cohort study reveals improved overall survival in advanced cutaneous melanoma, suggesting systemic therapy advances have substantially altered real-world clinical outcomes.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Nanz et al. (2026) studied this question.

synapsesocial.com/papers/6a9fd7c658e84d0ff5b46b5d https://doi.org/10.1111/ddg.70470

View Full Paper

Ask AI

Bookmark

Share

Improvement of overall survival in patients with cutaneous melanoma at a tertiary care center in Germany from 2001 to 2020

Key Points

No abstract yet

Implication

Discussion

Cite This Study

Improvement of overall survival in patients with cutaneous melanoma at a tertiary care center in Germany from 2001 to 2020

Key Points

No abstract yet

Implication

Discussion

Cite This Study

Keep reading

Keep reading